ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,119.14
0.42%
Dow Jones
43,408.47
0.00%
Gold vs US Dollar
2,665.205
0.48%
Brent Oil
74.01
1.61%
Bitcoin
97,762.82
3.61%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. TransCode Therapeutics Inc (RNAZ)

  7. TransCode Therapeutics Inc (RNAZ) News

TransCode Therapeutics (RNAZ)

TransCode Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:RNAZ
DateTimeSourceHeadlineSymbolCompany
13/11/202421:34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
12/11/202412:00GlobeNewswire Inc.TransCode Therapeutics Open Letter to ShareholdersNASDAQ:RNAZTransCode Therapeutics Inc
06/11/202421:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
06/11/202421:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
06/11/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
05/11/202412:00GlobeNewswire Inc.TransCode Therapeutics Announces Nasdaq Extension to Regain ComplianceNASDAQ:RNAZTransCode Therapeutics Inc
28/10/202420:02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
23/10/202411:00GlobeNewswire Inc.TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety DataNASDAQ:RNAZTransCode Therapeutics Inc
15/10/202421:23Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
10/10/202411:00GlobeNewswire Inc.TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted TechnologyNASDAQ:RNAZTransCode Therapeutics Inc
27/09/202420:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
17/09/202411:00GlobeNewswire Inc.TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic CandidateNASDAQ:RNAZTransCode Therapeutics Inc
10/09/202411:00GlobeNewswire Inc.TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic CancerNASDAQ:RNAZTransCode Therapeutics Inc
05/09/202411:00GlobeNewswire Inc.TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead CandidateNASDAQ:RNAZTransCode Therapeutics Inc
28/08/202410:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
16/08/202421:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
15/08/202411:00GlobeNewswire Inc.TransCode Therapeutics Announces Phase 1 Clinical Trial InitiationNASDAQ:RNAZTransCode Therapeutics Inc
14/08/202420:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNAZTransCode Therapeutics Inc
26/07/202420:05Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RNAZTransCode Therapeutics Inc
24/07/202420:05GlobeNewswire Inc.TransCode Therapeutics, Inc. Announces Closing of Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
24/07/202413:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
24/07/202412:18Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RNAZTransCode Therapeutics Inc
23/07/202402:30GlobeNewswire Inc.TransCode Therapeutics, Inc. Announces Pricing of Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
22/07/202420:10Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RNAZTransCode Therapeutics Inc
22/07/202420:07GlobeNewswire Inc.TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common StockNASDAQ:RNAZTransCode Therapeutics Inc
18/06/202420:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAZTransCode Therapeutics Inc
18/06/202420:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAZTransCode Therapeutics Inc
14/06/202412:00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
13/06/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
10/06/202412:45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RNAZ

Your Recent History

LSE
VAST
Vast Resources
LSE
POS
Plexus
LSE
SYME
Supply@me Capital
LSE
LIO
Liontrust Asset Management
LSE
MIN
Minoan
LSE
STX
Shield Therapeutics
LSE
GGP
Greatland Gold
LSE
DEC
Diversified Energy
LSE
LLOY
Lloyds Banking
LSE
ITM
Itm Power
LSE
POLX
Polarean Imaging
LSE
TERN
Tern
LSE
NEXN
Nexxen
LSE
MTRO
Metro Bank
LSE
AAZ
Anglo Asian Mining
LSE
JD.
Jd Sports Fashion
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Level 2 Lite

    1 year 40%, 2 years 50% and *3 years 60%
    EU Flag

    *Across 3 years £2132.64 only £853.06